TY - JOUR
T1 - A three-dimensional model of the δ-opioid pharmacophore
T2 - Comparative molecular modeling of peptide and nonpeptide ligands
AU - Shenderovich, Mark D.
AU - Liao, Subo
AU - Qian, Xinhua
AU - Hruby, Victor J.
PY - 2000
Y1 - 2000
N2 - A comparative molecular modeling study of δ-opioid ligands was performed under the assumption that potent peptide and nonpeptide agonists may have common three-dimensional (3D) arrangement of pharmacophore groups upon binding to the δ-receptor. Low-energy conformations of the agonists 7- spiroindanyloxymorphone (SlOM) and 2-methyl-4a-α-(3-hydroxyphenyl)- 1,2,3,4,4a, 5,12,12a-α-octahydro-quinolino[2,3,3-g]isoquinoline (TAN-67), and a partial agonist oxomorphindole (OMI) were determined by high- temperature molecular dynamics (MD). A good spatial overlap was found for the pharmacophore groups of SlOM, TAN-67, and OMI, including the basic nitrogen, phenol hydroxyl, and two aromatic ring. Based on this overlap we proposed a 3D pharmacophore model for nonpeptide δ-opioid agonists with a distance of 7.0 ± 1.3 Å between the two aromatic rings and of 8.2 ± 1.0 Å between the nitrogen and phenyl ring. The potent and highly δ-opioid receptor selective agonist [(2S, 3R)-TMT1]DPDPE, which shares global backbone constraints of the 14-membered disulfide cycle and a strong preference for the trans rotamer of the TMT-1 side chain, was chosen as a peptide template of the δ-opioid pharmacophore. Extensive MD simulations at 300 K with the AMBER force field were performed for [(2S, 3R)-TMT1]DPDPE and the less potent [(2S,3S)- TMT1]DPDPE analogue. Multiple MD trajectories were collected for each peptide starting from the x-ray structures of DPDPE and [L-Ala3]DPDPE and from models proposed in the literature. Low-energy MD conformations were filtered by the nonpeptide pharmacophore query and then directly superimposed with SIOM, OMI, and TAN-67. Two conformers of [(2S,3R)-TMT1]DPDPE that showed the best overlap with the nonpeptide pharmacophore (rms deviation ≤ 1.0 Å for N,O atoms and centroids of two aromatic rings) were selected as possible δ-receptor binding conformations. These conformations have similar backbone structures, and trans rotamers of the TMT1 side-chain group. They are reasonably close to the crystal structure of [L-Ala3]DPDPE, and differ significantly from the crystal structure of DPDPE. The conformer with a gauche(-) rotamer of Phe4 is most consistent with structure-activity relationships of δ-opioid peptides. The proposed 3D models were used for rational design of new nonpeptide δ-receptor ligands. (C) 2000 John Wiley and Sons, Inc.
AB - A comparative molecular modeling study of δ-opioid ligands was performed under the assumption that potent peptide and nonpeptide agonists may have common three-dimensional (3D) arrangement of pharmacophore groups upon binding to the δ-receptor. Low-energy conformations of the agonists 7- spiroindanyloxymorphone (SlOM) and 2-methyl-4a-α-(3-hydroxyphenyl)- 1,2,3,4,4a, 5,12,12a-α-octahydro-quinolino[2,3,3-g]isoquinoline (TAN-67), and a partial agonist oxomorphindole (OMI) were determined by high- temperature molecular dynamics (MD). A good spatial overlap was found for the pharmacophore groups of SlOM, TAN-67, and OMI, including the basic nitrogen, phenol hydroxyl, and two aromatic ring. Based on this overlap we proposed a 3D pharmacophore model for nonpeptide δ-opioid agonists with a distance of 7.0 ± 1.3 Å between the two aromatic rings and of 8.2 ± 1.0 Å between the nitrogen and phenyl ring. The potent and highly δ-opioid receptor selective agonist [(2S, 3R)-TMT1]DPDPE, which shares global backbone constraints of the 14-membered disulfide cycle and a strong preference for the trans rotamer of the TMT-1 side chain, was chosen as a peptide template of the δ-opioid pharmacophore. Extensive MD simulations at 300 K with the AMBER force field were performed for [(2S, 3R)-TMT1]DPDPE and the less potent [(2S,3S)- TMT1]DPDPE analogue. Multiple MD trajectories were collected for each peptide starting from the x-ray structures of DPDPE and [L-Ala3]DPDPE and from models proposed in the literature. Low-energy MD conformations were filtered by the nonpeptide pharmacophore query and then directly superimposed with SIOM, OMI, and TAN-67. Two conformers of [(2S,3R)-TMT1]DPDPE that showed the best overlap with the nonpeptide pharmacophore (rms deviation ≤ 1.0 Å for N,O atoms and centroids of two aromatic rings) were selected as possible δ-receptor binding conformations. These conformations have similar backbone structures, and trans rotamers of the TMT1 side-chain group. They are reasonably close to the crystal structure of [L-Ala3]DPDPE, and differ significantly from the crystal structure of DPDPE. The conformer with a gauche(-) rotamer of Phe4 is most consistent with structure-activity relationships of δ-opioid peptides. The proposed 3D models were used for rational design of new nonpeptide δ-receptor ligands. (C) 2000 John Wiley and Sons, Inc.
KW - Agonist
KW - Ligand
KW - Molecular modeling
KW - Nonpeptide
KW - Peptide
KW - δ-opioid pharmacophore
UR - http://www.scopus.com/inward/record.url?scp=0034057869&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034057869&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0282(200006)53:7<565::AID-BIP4>3.0.CO;2-5
DO - 10.1002/(SICI)1097-0282(200006)53:7<565::AID-BIP4>3.0.CO;2-5
M3 - Article
C2 - 10766952
AN - SCOPUS:0034057869
SN - 0006-3525
VL - 53
SP - 565
EP - 580
JO - Biopolymers
JF - Biopolymers
IS - 7
ER -